TABLE 1.

Drug name, nanoparticle composition, particle size, surface charge, route of administration, species of study, and dose of nanoparticles used for pharmacokinetic parameter estimations in this study

Drug Name	Matrix Material of Nanoparticles	Particle Size	Particle Charge	Route	Species	Dose Administered	Reference
		nm				mg/kg
Camptothecin IT-101	Polymer conjugate of camptothecin and β-cyclodextrin-based polymer	78	N.A.	Intravenous	Female Sprague-Dawley rats	1	Schluep et al., 2006
9-Nitrocamptothecin	Nanoparticles made with PLGA (50:50) and polyvinyl alcohol (PVA)	207 ± 26	N.A.	Intravenous	Male Wistar rats	2	Dadashzadeh et al., 2008
Epirubicin	Self-assembled system made with carboxymethyl curdlan coupled with cholesterol chitosan	208	Negative (−32.1)	Intravenous	Male Wistar rats	10	Li et al., 2010
Vinpocetine	Solid lipid nanoparticles made with glycerol monostearate, polysorbate 80, and soya lecithin	70.3 ± 7.8	Negative (−33.8 ± 0.9)	Oral	Male Wistar rats	10	Luo et al., 2006
Clozapine	Solid lipid nanoparticles made with triglyceride, phosphatidylcholine, poloxamer 188, and tripalmitin along with stearylamine	233 ± 13	Positive (+23.2 ± 0.9)	Duodenal and intravenous	Male Wistar rats	20	Manjunath and Venkateswarlu, 2005
Clozapine	Solid lipid nanoparticles made with triglyceride, phosphatidylcholine, poloxamer 188, and tripalmitin	163 ± 0.7	Neutral (+0.2 ± 0.1)	Duodenal and intravenous	Male Wistar rats	20	Manjunath and Venkateswarlu, 2005
Cyclosporine (positively charged NP)	Nanoparticles made with lecithin, poloxamer 188, and chitosan	148 ± 29	Positive (+31.2 ± 1.6)	Oral	Male beagle dogs	7.5	El-Shabouri, 2002
Cyclosporine (negatively charged NP)	Nanoparticles made with lecithin, poloxamer 188, and sodium glycocholate	104 ± 18	Negative (−41.6 ± 1.1)	Oral	Male beagle dogs	7.5	El-Shabouri, 2002

N.A., not available; NP, nanoparticles.